Published in Healthcare Mergers, Acquisitions and Ventures Week, February 3rd, 2007
As a result of this approval, Anthera will initiate a multicenter phase II clinical trial (PLASMA - Phospholipase Levels And Serological Markers of Atherosclerosis) that will examine the effect of A-002 on secretory phospholipase A2 (sPLA2) levels and other well established markers of inflammation and cardiovascular risk in patients with stable coronary artery disease due to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.